Can Carbon Quantum Dots (CQDs) or Boron Compounds be an Ultimate Solution for COVID-19 Therapy?

Document Type : Review Paper

Authors

1 Department of Pharmaceutical Technology, Faculty of Pharmacy, Biruni University, 34010, Topkapı, İstanbul, Turkey.

2 Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey.

10.22037/ijpr.2021.114856.15071

Abstract

Severe acute respiratory syndrome (SARS) is an infectious and highly transmissible disease that is affected by SARS coronavirus (SARS-CoV) and for which there are presently no approved treatments. COVID-19 is a new strain of coronavirus that has not been previously identified in humans. It is also a member of the coronaviruse family and known to cause similar illnesses in humans. The last outbreak has been identified as a Pandemic because of COVID-19 infections in humans. This review has been prepared to give some information to readers or scientists about some new generation of boron-doped or boron attached composite quantum dots during the design phase of the drug or drug delivery systems to be developed to combat COVID-19 and to help in the design of new drugs and systems by opening some new horizons. All scientists and researchers must quickly share their ideas and experiences in the fight against COVID-19 to find a better therapy or strategy for humans, and thus we can be successful. In this sense, this review offers readers some new ideas and rational perspectives. In conclusion, boron-containing composite carbon quantum dots appear to be the most suitable delivery system for treating COVID-19 infections especially when they are delivered through the lung.

Graphical Abstract

Can Carbon Quantum Dots (CQDs) or Boron Compounds be an Ultimate Solution for COVID-19 Therapy?

Keywords


  • Bar-On YM, Flamholz A, Phillips R and Milo R. SARS-Cov-2 (COVID-19) by the numbers. eLife (2020) 9: e57309
  • Gomes SAO, Vieira CS, Almeida DB, Santos-Mallet JR, Menna-Barreto RFS, Cesar CL and Feder D.CdTe and CdSe Quantum Dots Cytotoxicity: A Comparative Study on Microorganisms. (2011) 11: 11664–78.
  • Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY and Peiris JS. Lung pathology of fatal severe acute respiratory syndrome. Lancet (2003) 361: 1773–8.
  • Liu DX, Liang JQ and Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encyclopedia Virol. (2021) 2021: 428–40.
  • McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, Lewis J, Baer A, Kawakami V, Lukoff MD, Ferro J and Brostrom-Smith C. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. Engl. J. Med. (2020) 382: 2005-11.
  • Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth H, Klenk DS, Osterhaus AD, Schmitz H and Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. Engl. J. Med. (2003) 348: 1967–76.
  • Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ and SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. Engl. J. Med. (2003) 20: 1953–66.
  • Kopecki D, Lovelace B, Feuer W, Higginsdunn N. World Health Organization declares the coronavirus outbreak a global pandemic, March 11, 2020 (On line), Available from URL: https://www.cnbc.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-global-pandemic.html.
  • Qing H, Li Z, Yang Z, Shi M, Huang Z, Song J and Song Z. The possibility of COVID‐19 transmission from eye to nose. Acta Ophthalmol. (2020) 98: e388.
  • Puthiyedath R, Kataria S, Payyappallimana U, Mangalath P, Nampoothiri V, Sharma P, Singh MK, Kumar K and Trehan N. Ayurvedic clinical profile of COVID-19 – A preliminary report. Ayurveda Integr. Med. (2020)
  • Stoler J, Jepson WE and Wutich A. Beyond handwashing: Water insecurity undermines COVID-19 response in developing areas. Glob. Health (2020) 10: 010355.
  • Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TC, Littman DR and Landau NR. Identification of a major coreceptor for primary isolates of HIV-1. Nature (1996) 381: 661–6.
  • Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S and Cihlar T. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. Virol. (2003) 77: 5054–64.
  • Poutanen SM, Low DE, Henry N, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC and McGeer AJ. Identification of severe acute respiratory syndrome in Canada. Engl. J. Med. (2003) 348: 1995–2005.
  • Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, Wong PC, Lam B, Ip MS, Chan J, Yuen KY and Lai KN. A cluster of cases of severe acute respiratory syndrome in Hong Kong. Engl. J. Med. (2003) 348: 1977–85.
  • Van Vonderen MG, Bos JC, Prins JM, Wertheim-van Dillen P and Speelman P. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). J. Med. (2003) 61: 238–41.
  • Knowles SR, Phillips EJ, Dresser L and Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Infect. Dis. (2003) 37: 1139–42.
  • Cinatl J, Morgenstern B, Bauer G, Chandra P and Rabenau H. Treatment of SARS with human interferons. Lancet (2003) 362: 293–4.
  • Cinatl J, Morgenstern B, Bauer G, Chandra P and Rabenau H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet (2003) 361: 2045–6.
  • Bryant E. Final report confirms remdesivir benefits for COVID-19, NIH, October 20, 2020 (On line) Available from URL: https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19.
  • Moore JP and Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Natl. Acad. Sci. U.S.A. (2003) 100: 10598–602.
  • Este JA. Virus entry as a target for anti-HIV intervention. Med. Chem. (2003) 10: 1617–32.
  • Imai M, Okda N and Okada H. Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160. Immunol. (2000) 44: 205–12.
  • Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM and Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41- mediated virus entry. Med. (1998) 4: 1302–7.
  • Nikitenko YE, Raifeld AA and Wang TZ. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Med. Chem. Lett. (2001) 11: 1041–4.
  • Razinkov V, Gazumyan A, Nikitenko A, Ellestad G and Krishnamurthy G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Biol. (2001) 8: 645–59
  • Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S and Cihlar T. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. Virol. (2003) 77: 5054–64.
  • Bultmann H and Brandt CR. Peptides containing membrane transiting motifs inhibit virus entry. Biol. Chem. (2002) 277: 36018–23.
  • Bultmann H, Busse JS and Brandt CR. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. Virol. (2001) 75: 2634–45.
  • Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML and Spear PG. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Res. (1998) 40: 85–94.
  • Mullin R. Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B, November 24, 20145 (On line), Available from URL: https://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/.
  • El-Sherbiny IM, El-Baz NM and Yacoub MH. Inhaled nano- and microparticles for drug delivery. Cardiol. Sci. Pract. (2015) 2015: 2.
  • Healy SM, Amaro MI, Paluch KJ and Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Drug Deliv. Rev. (2014) 75: 32-52.
  • Tomasz G and Sosnowski TR. Formation of particles for dry powder inhalers. Powder Technol. (2014) 25: 43-55.
  • Degim IT and Kadioglu D. Cheap, Suitable, Predictable and Manageable Nanoparticles for Drug Delivery: Quantum Dots. Drug Deliv. (2013) 10: 32-8.
  • AOI (American Optronics Inc.) Engineering, Quantum dot. Available from URL: https://aoi-display.com/AOI/quantum-dot/ .
  • Fang M, Peng CW, Pang DW and Li Y. Quantum Dots for Cancer Research: Current Status, Remaining Issues, and Future Perspectives. Cancer Biol. Med. (2012) 9: 151–63.
  • Duncan TV. The communication challenges presented by nanofoods. Nanotechnol. (2011) 6: 683-8.
  • Bi J, Li Y, Wang H, Song Y, Cong S, Yu C, Zhu BW and Tan M. Presence and formation mechanism of foodborne carbonaceous nanostructures from roasted pike eel (Muraenesox cinereus). Agr. Food Chem. (2017) 66: 2862-9.
  • Martin L, Johannes S, Tommy C, Tord BR, Flanagan MB, Iseult L, Giuliano E and Kenneth D. The evolution of the protein corona around nanoparticles: A test study. ACS Nano. (2011) 5: 7503-9.
  • Yan Y, Gause KT, Kamphuis MMJ, Ang C, O’Brien-Simpson NM, Lenzo JC, Reynolds EC, Nice EC and Frank C. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. (2013) 7: 10960-70.
  • Huang R, Carney RP, Ikuma K, Stellacci F and Lau BLT. Effects of surface compositional and structural heterogeneity on nanoparticle protein interactions: Different protein configurations. ACS Nano. (2014) 8: 5402-12.
  • Chen D, Ganesh S, Wang W and Amiji MM. Role of surface chemistry on serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. Nanoscale (2019) 11: 8760-75.
  • Chen D, Ganesh S, Wang W and Amiji M. Plasma protein adsorption and biological identity of systemically administered nanoparticles. (2017) 12: 2113-35.
  • Nayak PS, Borah SM, Gogoi H, Asthana S, Bhatnagar R, Jha AN and Jha S. Lactoferrin adsorption onto silver nanoparticle interface: Implications of corona on protein conformation, nanoparticle cytotoxicity and the formulation adjuvanticity. Eng. J. (2019) 361: 470-84.
  • Hu W, Peng C, Lv M, Li X, Zhang Y, Chen N, Fan C and Huang Q. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano. (2011) 5: 3693-700.
  • Song Y, Wu Y, Wang H, Liu S, Song L, Li S and Tan M. Carbon quantum dots from roasted Atlantic salmon (Salmo salar): Formation, biodistribution and cytotoxicity. Food Chem. (2019) 293: 387-95.
  • Zhu RR, Wang WR, Sun XY, Liu H and Wang SL. Enzyme activity inhibition and secondary structure disruption of nano-TiO2 on pepsin. In Vitro (2010) 24: 1639-47.
  • Arumugam SS and Malaichamy I. Comprehensive multispectroscopic analysis on the interaction and corona formation of human serum albumin with gold/silver alloy nanoparticles. Phys. Chem. B (2015) 119: 9461-76.
  • Song Y, Wang H, Zhang L, Lai B, Liu K and Tan M. Protein corona formation of human serum albumin with carbon quantum dots from roasted salmon. Food Funct. (2020).
  • Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, Zhang H, Luo H, Zhu L, Jiang P, Chen L, Shen Y, Luo M, Zuo G, Hu J, Duan D, Nie Y, Shi X, Wang W, Han Y, Li T, Liu Y, Ding M, Deng H and Xu X. Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells. Virol. (2004) 11334–9.
  • Fang M, Chen M, Liu L and Li Y. Applications of Quantum Dots in Cancer Detection and Diagnosis: A Review. Biomed. Nanotechnol. (2017) 13: 1-16.
  • Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen YT, Metzler-Nolte N, Boukherroub R and Dubuisson J. Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. ACS Appl. Mater. Interfaces (2019) 11: 42964−74.
  • Friis-Hansen B, Aggerbeck B and Jansen JA. Unaffected blood boron levels in newborn infants treated with a boric acid ointment. Food Chem. Toxicol. (1982) 20: 451.
  • Stiittgen G, Siebel T and Aggerbeck B. Absorption of boric acid through human skin depending on the type of vehicle. Derm. Res. (1982) 272: 21.
  • Jansen JA, Schou JS and Aggerbeck B. Gastrointestinal absorption and in-vitro release of boric acid, from water-emulsifying ointments. Food Chem Toxicol (1983) 22: 49-53.
  • Farr LE, Konikowski T. The renal clearance of sodium pentaborate in mice and men. Clin. Chem. (1963) 9: 717.
  • Jansen JA, Andersen J and Schou JS. Boric acid single dose pharmacokinetics after intravenous administration to man. Toxicol. (1984) 55: 64-67.
  • Hadrup N, Fredericsen M, Sharma AK, Toxicity of boric acid, borax and other boron containing compounds: A review, Regulatory Toxicology and Pharmacology (2021) 121: 104873.
  • Rainey CJ, Nyquist LA, Christensen RE, Strong PL, Culver BD and Coughlin JR. Daily boron intake from the American diet. Am. Diet Assoc. (1999) 99: 335-40.
  • Hideghety K, Sauerwein W, Wittig A, Götz C, Paquis P, Grochulla F, Haselsberger K, Wolbers J, Moss R, Huiskamp R, Fankhauser H, de Vries M and Gabel D. Tissue uptake of BSH in patients with glioblastoma in the EORTC 1161 Phase I BNCT trial. Neuro. Oncol. (2003) 62: 145-56.
  • Zbigniew Jan Lesnikowski ZJ. Challenges and opportunities for the application of boron clusters in drug design. Med. Chem. (2016) 59: 7738–58
  • Baker SJ, Ding CZ, Akama T, Zhang YK, Hernandez V and Xia Y. Therapeutic potential of boron-containing compounds. Future Med. Chem. (2009) 1: 1275-88.
  • Markushin SG, Kantarov NA, Artiushenko SV, Akopova II, Koptiaeva IB and Bubnov LN. Investigation of antiviral activity of adamantan boron derivaties on pandemic influenza virus models. Khimioter. (2011) 56: 3-6.
  • Kandasamy, G. Recent Advancements in Doped/Co-Doped Carbon Quantum Dots for Multi-Potential Applications. J. Carob. Res. (2019) 5: 24-42.
  • Bourlinos AB, Trivizas G, Karakassides MA, Baikousi M, Kouloumpis, A, Gournis D, Bakandritsos A, Hola K, Kozak O, Zboril R, Papagiannouli I, Aloukos P and Couris S. Green and simple route toward boron doped carbon dots with significantly enhanced non-linear optical properties. Carbon (2015) 83: 173-9.
  • Lim SY, Shen W and Gao Z. Carbon quantum dots and their applications. Soc. Rev. (2015) 44: 362-81.